Cargando…

A new approach in acute myeloid leukemia (AML): Samatya-predicting score

We aimed to examine the efficiency for prediction of prognosis and response in non-APL AML cases of the “Samatya-predicting score”. A total of 213 patients diagnosed between January 2010-December 2020 were examined. Of the 158 patients included in the study, the median value of risk score was determ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Serin, Istemi, Orhan, Bagnu, Sonmez, Derya, Cinli, Tahir Alper, Goze, Hasan, Serin, Huriye, Gulesir, Begum, Yokus, Osman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866886/ https://www.ncbi.nlm.nih.gov/pubmed/35242525 http://dx.doi.org/10.1016/j.lrr.2022.100293

Ejemplares similares

PB1752: SAMATYA-PREDICTING SCORE IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): COMBINING CLINICAL FEATURES WITH FLOW CYTOMETRY
por: Cinli, Tahir Alper, et al.
Publicado: (2023)

PB1841: A NEW APPROACH IN ACUTE MYELOID LEUKEMIA (AML): SAMATYA-PREDICTING SCORE
por: Serin, I., et al.
Publicado: (2022)

Iron overload during the treatment of acute leukemia: pretransplant transfusion experience
por: Yokus, Osman, et al.
Publicado: (2021)

A Huge Mass in the Liver: Plasmacytoma
por: Cinli, Tahir Alper, et al.
Publicado: (2022)

Lateral flow assay (LFA) in the diagnosis of COVID-19-associated pulmonary aspergillosis (CAPA): a single-center experience
por: Serin, Istemi, et al.
Publicado: (2022)

PB2334: CENTRAL NERVOUS SYSTEM (CNS) RELAPSE IN DIFFUSE LARGE B-CELL LYMPHOMA: CNS-SAMATYA RISK MODEL
por: Yokus, Osman, et al.
Publicado: (2023)

Secondary Immunodeficiency Frequency in Patients with Chronic Lymphocytic Leukemia: The Relationship with Stage and Treatment
por: Yokus, Osman, et al.
Publicado: (2022)

Prognostic Role of Lymphocyte/Monocyte Ratio in Chronic Lymphocytic Leukemia
por: Yokus, Osman, et al.
Publicado: (2020)

A case report: paroxysmal nocturnal hemoglobinuria and systemic lupus erythematosus association
por: Serin, Istemi, et al.
Publicado: (2020)

PB2075: HOW EFFECTIVE ARE LEPTIN GENE POLYMORPHISMS AND METHYLATION DURING THE COURSE OF MULTIPLE MYELOMA (MM)?
por: Serin, Istemi, et al.
Publicado: (2023)

Enigma of COVID-19: is “multisystem inflammatory syndrome in adults” (MIS-A) predictable?
por: Serin, Istemi, et al.
Publicado: (2022)

PB2237: NON-THROMBOTIC INCREASED PORTAL VENOUS PRESSURE IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: IS IT JUST A HYPOTHESIS?
por: Yokus, Osman, et al.
Publicado: (2023)

PB2234: EFFECT OF HYDROXYUREA ON INFLAMMATORY MARKERS IN PATIENTS WITH BCR-ABL NEGATIVE MYELOPROLIFERATIVE DISEASES
por: Altunok, Oguz, et al.
Publicado: (2023)

PB2400: THE EFFECT OF BONE MARROW CD4/CD8+ RATIO ON RESPONSE TO TREATMENT AND SURVIVAL IN LYMPHOMAS
por: Can Cavdar, Vahit, et al.
Publicado: (2023)

PB2245: POLYCYTHEMIA VERA (PV) AND SECONDARY POLYCYTHEMIA (SP): ARE METABOLIC DIFFERENCES JUST THEORIES?
por: Yokus, Osman, et al.
Publicado: (2023)

PB2321: THE EFFECT OF PRE-TREATMENT SERUM KINDLIN-3 ON HODGKIN AND NON-HODGKIN LYMPHOMAS: A SINGLE CENTER EXPERIENCE
por: Keskin, Melike, et al.
Publicado: (2023)

Gilteritinib (XOSPATA®) in Turkey: Early Access Program Results
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2023)

PB1897: GILTERITINIB IN TURKEY: EARLY ACCESS PROGRAM RESULTS
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2023)

Chromosomal rearrangements in acute myeloid leukemia (AML)
por: Belloni, E, et al.
Publicado: (2010)

New agents in acute myeloid leukemia (AML)
por: Park, Silvia, et al.
Publicado: (2020)

AngioCRIME in Acute Myeloid Leukemia (AML)
por: Macintyre, Elizabeth
Publicado: (2017)

DNA Repair Genes and Chronic Myeloid Leukemia: ERCC2 (751), XRCC1 (399), XRCC4-Intron 3, XRCC4 (-1394) Gene Polymorphisms
por: Ozdilli, Kursat, et al.
Publicado: (2021)

Charlson Comorbidity Index (CCI) in Diffuse Large B-cell Lymphoma: A New Approach in a Multicenter Study
por: Eren, Rafet, et al.
Publicado: (2022)

Alkaline phosphatase interference in immuno-enzymatic assays
por: Oğuz, Osman, et al.
Publicado: (2022)

To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission
por: Sevindik, Omur Gokmen, et al.
Publicado: (2022)

A new parameter in COVID-19 pandemic: initial lactate dehydrogenase (LDH)/Lymphocyte ratio for diagnosis and mortality
por: Serin, Istemi, et al.
Publicado: (2020)

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)
por: Assouline, Sarit, et al.
Publicado: (2012)

Switch of the mutation type of the NPM1 gene in acute myeloid leukemia (AML): relapse or secondary AML?
por: Webersinke, G, et al.
Publicado: (2014)

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?
por: Yilmaz, Musa, et al.
Publicado: (2019)

The use of hypomethylating agents in hematologic malignancies: treatment preferences and results
por: Serin, Istemi, et al.
Publicado: (2021)

New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML)
por: Chen, Jing, et al.
Publicado: (2020)

Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?
por: Guolo, Fabio, et al.
Publicado: (2022)

Choosing the Right Cell Line for Acute Myeloid Leukemia (AML) Research
por: Skopek, Rafał, et al.
Publicado: (2023)

Acute Myeloid Leukemia (AML) with Erythroid Predominance Exhibits Clinical and Molecular Characteristics that Differ from Other Types of AML
por: Zuo, Zhuang, et al.
Publicado: (2012)

Prognostic prediction of novel risk scores (AML-DRG and AML-HCT-CR) in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation
por: Cao, Weijie, et al.
Publicado: (2022)

Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
por: Hofmann, Susanne, et al.
Publicado: (2019)

Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches
por: Winer, Eric S., et al.
Publicado: (2019)

Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes
por: Matre, Polina, et al.
Publicado: (2016)

Integrated N- and O-Glycomics of Acute Myeloid Leukemia (AML) Cell Lines
por: Blöchl, Constantin, et al.
Publicado: (2021)

Chemotherapy as Treatment for Acute Myeloid Leukemia (AML)-Induced Facial Nerve Palsy
por: Fana, Michael, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_itf45br6ref5j2td03s4de9orp